NCT00519064View on ClinicalTrials.gov

Immunogenicity and Safety of an Adjuvanted Inactivated Subunit Influenza Vaccine to Those of a Non-adjuvanted Inactivated Subunit Influenza Vaccine, When Administered to Adults Affected by Chronic Diseases

PHASE3CompletedINTERVENTIONAL
Enrollment

361

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

December 31, 2006

Study Completion Date

May 31, 2007

Conditions
Influenza Disease
Interventions
BIOLOGICAL

Adjuvanted influenza vaccine

Trial Locations (1)

30034

Azienda ULSS 13 di Mirano, Mira, Via Nazionale 48

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY

NCT00519064 - Immunogenicity and Safety of an Adjuvanted Inactivated Subunit Influenza Vaccine to Those of a Non-adjuvanted Inactivated Subunit Influenza Vaccine, When Administered to Adults Affected by Chronic Diseases | Biotech Hunter | Biotech Hunter